6492 Stock Overview
A drug development company, engages in the development of new drugs and targeted agents. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Senhwa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$34.65 |
| 52 Week High | NT$64.50 |
| 52 Week Low | NT$28.45 |
| Beta | 0.80 |
| 1 Month Change | 10.88% |
| 3 Month Change | -23.68% |
| 1 Year Change | -17.70% |
| 3 Year Change | -56.14% |
| 5 Year Change | -74.04% |
| Change since IPO | -66.68% |
Recent News & Updates
Shareholder Returns
| 6492 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 6.0% | 0.5% | 0.07% |
| 1Y | -17.7% | -5.3% | 0.1% |
Return vs Industry: 6492 underperformed the TW Biotechs industry which returned -5.3% over the past year.
Return vs Market: 6492 underperformed the TW Market which returned 0.1% over the past year.
Price Volatility
| 6492 volatility | |
|---|---|
| 6492 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in TW Market | 10.2% |
| 10% least volatile stocks in TW Market | 4.9% |
Stable Share Price: 6492 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6492's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Jason Huang | www.senhwabio.com |
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma.
Senhwa Biosciences, Inc. Fundamentals Summary
| 6492 fundamental statistics | |
|---|---|
| Market cap | NT$3.09b |
| Earnings (TTM) | -NT$291.96m |
| Revenue (TTM) | NT$1.00m |
Is 6492 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6492 income statement (TTM) | |
|---|---|
| Revenue | NT$1.00m |
| Cost of Revenue | NT$530.00k |
| Gross Profit | NT$470.00k |
| Other Expenses | NT$292.44m |
| Earnings | -NT$291.96m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.27 |
| Gross Margin | 47.00% |
| Net Profit Margin | -29,196.50% |
| Debt/Equity Ratio | 0% |
How did 6492 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 19:50 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senhwa Biosciences, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Jane Jiang | Yuanta Research |